AAV-based delivery of RNAi targeting Ataxin-2 improves survival, strength, and pathology in mouse models of rapidly and slowly progressive sporadic ALS
Defne A. Amado(Children's Hospital of Philadelphia), Beverly L. Davidson(Children's Hospital of Philadelphia)
Cited by 6
Related Papers
Current prospects for RNA interference-based therapies
|Nature Reviews Genetics|2011|757
The Bifunctional microRNA miR-9/miR-9* Regulates REST and CoREST and Is Downregulated in Huntington's Disease
|Journal of Neuroscience|2008|681